324 results on '"Tushuizen, Maarten E."'
Search Results
2. Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD
3. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial
4. Coronary artery calcium assessment on non-gated chest CT to optimize pre-operative cardiac screening in liver transplantation
5. Diagnostic criteria and long-term outcomes in AIH-PBC variant syndrome under combination therapy
6. An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis
7. Bacterial Infections After Liver Transplantation and the Role of Oral Selective Digestive Decontamination: A Retrospective Cohort Study
8. Intraprocedural assessment of ablation margins using computed tomography co-registration in hepatocellular carcinoma treatment with percutaneous ablation: IAMCOMPLETE study
9. Survival benefit from liver transplantation for patients with and without hepatocellular carcinoma
10. Skeletal muscle mass in patients with end-stage liver disease: Not only muscle size but especially muscle quality matters in relation to physical fitness
11. Microbiome-derived ethanol in nonalcoholic fatty liver disease
12. Study Protocol: Adjuvant Holmium-166 Radioembolization After Radiofrequency Ablation in Early-Stage Hepatocellular Carcinoma Patients—A Dose-Finding Study (HORA EST HCC Trial)
13. Fecal transplant
14. Nonalcoholic fatty liver disease
15. List of contributors
16. Validation of the enhanced liver fibrosis (ELF)-test in heparinized and EDTA plasma for use in reflex testing algorithms for metabolic dysfunction-associated steatotic liver disease (MASLD)
17. Study Protocol PROMETHEUS: Prospective Multicenter Study to Evaluate the Correlation Between Safety Margin and Local Recurrence After Thermal Ablation Using Image Co-registration in Patients with Hepatocellular Carcinoma
18. Joint modeling of liver transplant candidates outperforms the model for end-stage liver disease: The effect of disease development over time on patient outcome
19. Both muscle quantity and quality are predictors of waiting list mortality in patients with end-stage liver disease
20. Development and validation of a dynamic survival prediction model for patients with acute-on-chronic liver failure
21. Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region
22. Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study):a study protocol for a phase III, open-label, multicentre, randomised controlled trial
23. Liver Injury and Acute Liver Failure After Bariatric Surgery: An Overview of Potential Injury Mechanisms
24. Primary sclerosing cholangitis and other risk factors for post-transplant lymphoproliferative disease after liver transplantation in adults.
25. Metabolic dysfunction associated steatotic liver disease and the heart
26. Commentary: Commentary: Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment
27. Primary sclerosing cholangitis and other risk factors for post-transplant lymphoproliferative disease after liver transplantation in adults
28. A global survey of health care workers' awareness of non‐alcoholic fatty liver disease: The AwareNASH survey
29. Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment
30. The impact of CYP2C19 genotype on phenoconversion by concomitant medication
31. Association between skeletal muscle index prior to liver transplantation and one‐year mortality post‐transplant: A retrospective cohort study
32. Step forward in early recognition of systemic sclerosis: data from the Leiden CCISS cohort
33. Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation: DELTA Study
34. Quality assessment of donor liver procurement surgery using an unadjusted CUSUM prediction model. A practical nationwide evaluation
35. Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease
36. Epstein–Barr Viral Load Monitoring Strategy and the Risk for Posttransplant Lymphoproliferative Disease in Adult Liver Transplantation
37. Invited response to “MELD calibration”
38. Commentary:Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment
39. Randomized Trial of Ciclosporin with 2-h Monitoring vs. Tacrolimus with Trough Monitoring in Liver Transplantation:DELTA Study
40. Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis
41. Antibodies against multiple post-translationally modified proteins aid in diagnosis of autoimmune hepatitis and associate with complete biochemical response to treatment
42. A global survey of health care workers' awareness of non-alcoholic fatty liver disease:The AwareNASH survey
43. A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey
44. Association between skeletal muscle index prior to liver transplantation and 1‐year mortality posttransplant.
45. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
46. Importance of complete response for outcomes of pregnancy in patients with autoimmune hepatitis
47. Author response: FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis
48. Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-α/γ agonist aleglitazar
49. Tacrolimus 4‐hour monitoring in liver transplant patients is non‐inferior to trough monitoring: The randomized controlled FK04 trial
50. Nonalcoholic fatty liver disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.